JYNARQUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JYNARQUE (JYNARQUE).
Vasopressin V2 receptor antagonist. Binds to V2 receptors in renal collecting ducts, blocking antidiuretic hormone (ADH) action, thereby increasing water excretion without altering sodium/potassium excretion.
| Metabolism | Primarily metabolized by CYP3A4; minor pathways: CYP2C8, UGT1A9, UGT2B7. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites; <1% excreted unchanged in urine; 9.1% of dose recovered in feces as unchanged drug. |
| Half-life | Terminal elimination half-life approximately 25-30 hours, supporting twice-daily dosing for steady-state concentrations. |
| Protein binding | 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 30 L (0.43 L/kg for a 70 kg adult), indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability approximately 42-66% (median 50%); food reduces peak concentration but not overall exposure (AUC unchanged). |
| Onset of Action | Oral: Reduction in urine osmolality and increase in urine volume occur within 2 hours of first dose; maximal effect on urine osmolality at 4-8 hours. |
| Duration of Action | Duration of aquaretic effect is dose-dependent; at therapeutic doses, effects persist for 12-24 hours, consistent with twice-daily dosing. |
15 mg orally twice daily initially; titrate to 60 mg once daily and 30 mg once daily (90 mg total daily) or 90 mg once daily based on tolerability.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: no adjustment recommended. eGFR 15-29 mL/min: use is not recommended. eGFR <15 mL/min: contraindicated. Dialysis: not studied. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce maximum dose to 60 mg once daily. Child-Pugh Class C: avoid use. |
| Pediatric use | Not established; no FDA-approved pediatric dosing. Safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No specific dose adjustment recommended; consider age-related renal function and monitor volume status due to increased risk of adverse events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JYNARQUE (JYNARQUE).
| Breastfeeding | No data on human milk excretion; M/P ratio unknown. Due to potential adverse effects in nursing infants, avoid breastfeeding during treatment. |
| Teratogenic Risk | First trimester: Increased risk of fetal malformations based on animal studies; consider contraception. Second and third trimesters: Potential for nephrotoxicity and oligohydramnios due to V2 receptor antagonism. |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: RISK OF SERIOUS LIVER INJURY. JYNARQUE can cause serious and potentially fatal liver injury. Measure ALT, AST, and bilirubin before starting treatment, monthly for 18 months, then every 3 months thereafter. Discontinue if liver injury suspected.
| Serious Effects |
History of or liver disease/injury; uncontrolled hypernatremia or hypovolemia; taking strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin); reduced kidney function (eGFR <25 mL/min/1.73m²); inability to sense or respond to thirst; pregnant or breastfeeding.
| Precautions | Hepatotoxicity; elevation of liver enzymes; aquaretic effects (polyuria, nocturia, thirst, dehydration, hypernatremia); electrolyte disturbances; avoid use with strong CYP3A4 inhibitors; monitor renal function and electrolytes; contraindicated in patients with reduced kidney function (eGFR <25 mL/min/1.73m²) or unable to sense thirst. |
Loading safety data…
| Pregnancy test before initiation; monitor renal function, electrolytes, liver enzymes, and amniotic fluid volume during pregnancy. |
| Fertility Effects | In females, may impair fertility due to hormonal contraceptive interaction; in males, no significant effects reported. |